Oral IL-23 Blocker for Psoriasis Promising: Phase 2b Study ...Middle East

Medscape - News
An investigational IL-23R antagonist demonstrated significantly greater efficacy across all doses in patients with moderate to severe psoriasis compared with placebo at week 16 in the FRONTIER 1 study. Medscape Medical News

Hence then, the article about oral il 23 blocker for psoriasis promising phase 2b study was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Oral IL-23 Blocker for Psoriasis Promising: Phase 2b Study )

Apple Storegoogle play

Last updated :

Also on site :



Latest News